U.S., Nov. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07244666) titled 'Safety and Preliminary Efficacy of a Metabolically Armed Chimeric Antigen Receptor T Cell Therapy Targeting EGFRvIII for Recurrent Glioblastoma' on Nov. 17.
Brief Summary: A Study of Metabolically Armed EGFRvII CAR-T Cells Therapy for Patients With Recurrent Glioblastoma
Study Start Date: Nov. 15
Study Type: INTERVENTIONAL
Condition:
Glioblastoma (GBM)
Intervention:
DRUG: Metabolically Armed EGFRvIII CAR-T cells
Patients will receive a single infusion of Meta10-EGFRvIII.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Published by HT Digital Content Servic...